Johnson & Johnson patent lawsuit agains Boston Scientific's NIR stent dismissed in Canada
09 May 2008
The Canadian Federal Court has dismissed Johnson & Johnson's lawsuit accusing rival cardiac stentmaker Boston Scientific's NIR stent of infringing two Johnson & Johnson Palmaz patents. The court found that the the Boston Scientific stent did not infringe one patent of Johnson & Johnson, and found the other patent invalid. The trial had taken place earlier this year.
Johnson & Johnson recently filed a second lawsuit in Canada in which it cliamed that Boston Scientific's Express and Taxus Express stents of infringing the same two patents.
"We are very pleased with the decision by the Canadian Federal Court dismissing this case," said Paul LaViolette, Boston Scientific's chief operating officer. "The ruling affirms our position that our products do not infringe these patents. We also believe our Express and Taxus Express coronary stents do not infringe - as alleged by Johnson & Johnson - and are hopeful the Court will reach the same conclusion."
Boston Scientific is a global developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.
